Clinical Infectious Diseases · 19 Nov 2026
Pharmacokinetic/Pharmacodynamic Analysis of Standard- and High-Dose Rifampicin to Predict Safety, Completion, and Tolerability of Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial
Fajri Gafarh-index 7, Elin M Svensson, Vycke Yunivita, Federica Fregonese, Dina Fisher, Greg J Fox, Thu Anh Nguyen, Binh Hoa Nguyen, James Johnston, Richard Long, Lika Apriani, Chantal Valiquette, Rob E Aarnoutse, Rovina Ruslami, Dick Menzies, the 2R2 trial investigators, Leila Barss, Rachel K Lim, Nancy Bedingfield, Andrea Benedetti, Diana Gibson, Victor Chiang, Victoria J Cook, Eri Flores, Catherine Paulsen, Nguyen Viet Nhung
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract Background Rifampicin-based tuberculosis preventive therapy (TPT) may shorten treatment duration, but substantial interindividual pharmacokinetic variability may lead to different safety and tolerability profiles at the same dose. We performed pharmacokinetic/pharmacodynamic analyses of standard- and high-dose rifampicin to predict safety, completion, and tolerability. Methods We analyzed data from 1368 adults and adolescents enrolled in the 2R2 trial comparing 2 months of rifampicin at 20 or 30 mg/kg/day with 4 months at 10 mg/kg/day. A population pharmacokinetic model developed from 440 participants was used to predict rifampicin exposure for all participants. Missing exposure metrics were imputed using 1000 simulated datasets. Exposure-response relationships were evaluated using multivariable logistic regression models fitted within imputed datasets, with coefficients and standard errors pooled across imputations. Results A 2-fold increase in total rifampicin exposure (AUC0-24) was associated with higher odds of protocol-defined adverse events (AEs) requiring permanent discontinuation (aOR 1.88, 95% CI 1.25–2.81), discontinuation unrelated to AEs (aOR 1.42, 95% CI 1.15–1.75), and tolerability symptoms potentially related to AEs without discontinuation (aOR 1.48, 95% CI 1.18–1.86); similar patterns were observed for peak concentration (Cmax). Higher AUC0-24 and Cmax were also associated with grade 1–2 and grade 3–4 AEs, rash/allergy/hypersensitivity, gastrointestinal intolerance, and early discontinuation, with no significant association for hepatotoxicity. Exposure-based models showed slightly better discriminatory performance than dose-based models in predicting safety. Conclusions Higher rifampicin exposure was associated with worse safety, completion, and tolerability in TPT. Larger efficacy trials are needed to determine the optimal dose to achieve sufficient exposure, alongside investigation of therapeutic drug monitoring to avoid excessive exposure. Clinical Trials Registration The 2R2 trial was registered at https://clinicaltrials.gov/, identifier: NCT03988933.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Fajri Gafar has the highest h-index among the authors (7).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (40)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 20 more references
A free account opens the rest of the citing papers and references on every paper’s page.